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Abstract
Loss in body mass (ΔBM) is a common feature in patients with Alzheimer’s disease (AD).
However, the etiology of this phenomenon is unclear. The aim of this cohort study was to
observe possible ΔBM in AD patients following a standard institutionalized diet. Secondary
objective was to identify possible predictors of ΔBM. To this end, 85 AD patients (age: 76±4
yrs; stature: 165±3 cm; BM: 61.6±7.4 kg; mean±standard deviation) and 86 controls (CTRL;
age: 78±5 yrs; stature: 166±4 cm; BM: 61.7±6.4 kg) were followed during one year of stan-
dard institutionalized diet (~1800 kcal/24h). BM, daily energy expenditure, albuminemia,
number of medications taken, and cortisolism, were recorded PRE and POST the observa-
tion period. Potential predictors of ΔBM in women (W) and men (M) with AD were calculated
with a forward stepwise regression model. After one year of standard institutionalized diet,
BM decreased significantly in AD (-2.5 kg; p < 0.01), while in CTRL remained unchanged
(-0.4 kg; p = 0.8). AD patients and CTRL exhibited similar levels of daily energy expenditure
(~1625 kcal/24h). The combination of three factors, number of medications taken, albumi-
nemia, and cortisolism, predicted ΔBM in W with AD. At contrary, the best predictor of ΔBM
in M with AD was the cortisolism. Despite a controlled energy intake and similar energy
expenditure, both W and M with AD suffered of ΔBM. Therefore, controlled diet did not pre-
vent this phenomenon. The assessments of these variables may predict W and M with AD
at risk of weight loss.
Introduction
Changes in body composition, such as loss in total body mass (BM) affect adversely physical
function and quality of life of patients with Alzheimer’s disease (AD) [1]. Such a change could
be the result of an unbalance between energy intake and energy expenditure [2]. For instance,
weight loss (WL) can be prevented in patients with dementia by increasing their energy intake
[3]. On the other side, a murine study suggested that AD is associated with a hyper-metabolic
state, which may affect daily energy expenditure (DEE) and body composition [4]. Conversely,
the resting metabolic rate (RMR) in humans was found to be similar in patients with AD and
in healthy old individuals [5]. Moreover, patients with AD usually demonstrate an increased
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level of daily physical activity (PA) induced by behavioral disorders, such as wandering, that
may likely increase the DEE [6].
Given their chronic treatment with medications, the potential contribution of pharmacolog-
ical therapy in patients with AD to the aforementioned changes in body composition has been
recently debated [2, 7]. Recognized side effects of medications, such as antidepressants, cholin-
esterase inhibitors, and corticosteroids drugs, include gastrointestinal symptoms, such as nau-
sea, vomiting and diarrhea [8] that may affect as well BM. Moreover, pharmacological
interactions may potentially increase the side effects affecting body composition.
Strong evidence indicates that AD is associated with a dysregulation of the hypothalamic–
pituitary–adrenal axis (HPA-axis) [9], with a clear increase in cortisol levels [10]. The effects of
hypercortisolism are wide-ranging, affecting widely the skeletal muscle, thus leading to a
remarkable sarcopenia.
Lastly, growing literature supports the theory that oxidative damage is associated with the
pathogenesis and development of AD [11]. It was recognized that albumin plasma levels, the
main antioxidants plasma carrier, are significantly reduced in patients with AD [12]. Addition-
ally, elevated oxidative stress markers are normally associated with the increased numbers of
neutrophils in patients with AD [13]. However, their role in the WL remains not clear.
Therefore, the aim of the present cohort study was to observe possible BM changes in AD
patients following a standard institutionalized diet. Secondary aim was to determine the contri-
bution of energy intake and expenditure, reduction in antioxidants plasma carrier, pharmaco-
logical treatments, hypercortisolism, and chronic inflammation to the WL in patients with AD.
The assessment of these values may help to predict this challenging clinical phenomenon.
Methods
Study design
This cohort study compared the effects of 12 months standard institutionalized diet in a group
of patients with AD and age-matched controls (CTRL) without symptoms of dementia (Fig 1
and S1 File). BM, mobility performance, cognitive function, blood pressure, blood sample,
daily energy expenditure, and salivary cortisol levels were assessed at baseline and after
12-month of standard institutionalized diet.
Participants
Eligible volunteers were selected among nursing home residents of Alzheimer’s care units and
standard geriatrics care units at the Mons. Mazzali Geriatric Institute in Mantua, Italy. Inclu-
sion criteria were an age>65 yrs. Being both energy expenditure and intake two key factors
analyzed in this study, patients with mobility limitations (performance-oriented assessment of
mobility problems, POMA) [14] score lower than 25, and subjects with nutritional support
(parenteral nutrition), were not included in the study. Moreover, patients with dysphagia, can-
cer related cachexia, were not selected for the study.
Screening
From October 2013, three hundred sixty-three volunteers were screened for eligibility, 171 sub-
jects met the above mentioned inclusion criteria. Eighty-five residents of the Alzheimer’s care
units (27 men and 58 women) with a confirmed diagnosis of Alzheimer’s diseases dementia,
and 86 residents of standard geriatrics care units (CTRL, 23 men and 63 women) without clini-
cal evidence of dementia, were selected for the study. Selected participants were than moni-
tored from January 2014 to January 2015. Patients’ relatives or legal representatives and CTRL
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received written and oral information about the study before signing the informed consent
form. The University of Milan ethical committee approved the study (approval number 63/14).
The study was carried out in accordance with the Declaration of Helsinki (2013) of the World
Fig 1. Participant flow diagram. AD, Alzheimer’s disease; CTRL, controls; BM, body mass; Nmed, number of medications; MMSE, Mini-
Mental State Examination; ADL, activities of daily life; POMA; performance-oriented assessment of mobility.
doi:10.1371/journal.pone.0157384.g001
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Medical Association for experiments involving humans. Characteristics of the participants are
reported in Table 1.
Test procedures
Primary and secondary outcome measures were assessed at baseline and after 12-month of
standard institutionalized diet. The medical staff monitored the category and total number of
medications (NMED) taken by the participants.
Controlled diet
During the 12-month standard institutionalized diet, 5 balanced meals per day (~1800
kcal!24h-1) were offered to the participants. It is important to note that the diet adopted for this
observational study was part of their usual care, and was defined by a professional nutritionist
of the Mons. Mazzali Foundation following the national guidelines of the Italian Department
of Health for institutionalized patients [15]. More in details, breakfast (served at 7.00 AM) con-
sisted of 200 ml of skimmed milk, 50 g of bread with two teaspoons of jam or honey; morning
snack (served at 10.00 AM) contained 125 g of yogurt and cereals, or one fresh fruit (free choice
among banana, apple or peach); lunch (served at noon) was composed by 80 g of pasta or rice,
100 g of meat or fish and one cup of fresh vegetables with lite dressing, such as olive oil; after-
noon snack (served at 4.00 PM) consisted in a cup of tea with three or four dry cookies, or one
Table 1. Demographic and clinical characteristics of the study participants at baseline. Values are
expressed as mean ± standard deviation (or percentage in brackets).
Characteristic CTRL AD
(N = 86) (N = 85)
Age—yrs 78 ± 5 76 ± 4
Female sex—no. (%) 63 (73) 58 (68)
Body mass index (kg!m-2) 23 ± 3 23 ± 4
Duration of disease—yrs - 8 ± 2
Duration of nursing home living—yrs 3.9 ± 2.1 3.2 ± 2.5
Participants taken medications–no. (%)
Quetiapine 1 (1) 29 (32) *
Citalopram 8 (9) 26 (30) *
Donepezil - 6 (7) *
Memantine - 2 (2) *
Ticlopidin 3 (3) 12 (14) *
Furosemide 4 (4) 15 (18) *
Bisoprolol 15 (17) 12 (14)
Rabeprazol 24 (28) 35 (41)
Acetylsalicylic acid 44 (51) 26 (30) *
Mean number of medications–no. 3 ± 1 6 ± 1 *
Severity of dementia (CDR 0–3) - 2 ± 1
Behavioral disturbance (NPI) - 68 ± 19
Coexisting chronic conditions—no. (%)
0 4 (5) 5 (5)
1 14 (16) 19 (23)
"2 68 (79) 61 (72)
* P<0.05 vs CTRL.
doi:10.1371/journal.pone.0157384.t001
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fresh fruit (free choice among banana, apple or peach); dinner (served at 7.00 PM) comprised
100 g of soup, 50 g of bread, 100 g of meat or fish and half a cup of boiled vegetables with lite
dressing.
Adherence to the standard institutionalized diet
Nurses, caregivers and relatives assisting the patient’s during breakfast, lunch, and dinner were
instructed to record into a database file any discrepancy between offered and eaten meals. To
calculate the adherence to the diet, the amount of calories for additional or not eaten meals was
estimated by weighting the food. Percent difference between offered and eaten meals was than
calculated for each participant. Values of daily energy intake reported in the text represent the
amount of calories calculated from the daily eaten meals.
Primary outcome
Fasted BM was measured in the morning with a professional mechanical scale fitted with a sta-
diometer (Seca mod. 713; III-M; Seca Medical Scales and Measuring Systems, Birmingham,
UK).
Secondary outcomes
Clinical Dementia Rating (CDR) [16], Mini-Mental State Examination (MMSE) [17], and
Neuro-Psychiatric Inventory (NPI) [18] were utilized to determinate progression and severity
of dementia, as well as behavioral disorders. Nursing home residents’ gait and balance perfor-
mance were assessed using the POMA [14]. Independence and level of activities of daily life
(ADL) were evaluated with the Barthel index [19]. Fasted venous blood samples were analyzed
for glucose, red blood cells, hemoglobin, high- and low-density lipoprotein blood levels, creati-
nine, azotemia, and hepatic function by standard techniques. Inflammation state was estimated
from white blood cells count (WBC) and the percent difference in neutrophils, eosinophils,
basophils, and lymphocytes. Plasma level of albumin (ALB) was utilized for the determination
of antioxidants carrier. Blood level of retinol was utilized to control the effectiveness of the diet
and the nutritional state of the participants. Levels of cortisol (COR) were measured via saliva
samples using plain Sarstedt Salivette collection devices (Nümbrecht, Germany). Samples were
collected at 6.30 AM, 11.30 AM, and 6.30 PM. Immediately after collecting the saliva samples,
the Salivette tubes were centrifuged for 2 min at 1,000 rpm. Purified saliva were stored in a
freezer at -20°C, and subsequently analyzed. COR levels were determined by a time-resolved
immunoassay with fluorometric detection. For comparisons, each time point of COR levels
were utilized, as well as the daily average level. DEE was measured with an Actiheart device
(CamNtech, Cambridge, UK) allowing heart rate and acceleration data to be simultaneously
recorded for 24 h/day for 7 consecutive days. The PA and the RMR components of daily energy
expenditure were then calculated with a specific algorithm [20].
Predictors of BM changes in patients with AD
To evaluate potential demographic covariant of pre-to-post changes in BM (ΔBM), secondary
outcomes assessed at baseline in patients with AD has been described with sex- and age-adjust-
ment (less than 75 yrs; between 75 and 80 yrs; more than 80 yrs). Subsequently, being only the
sex a potential covariant for ΔBM, in W and M with AD a univariate Pearson’s correlation
model was performed to evaluate the single correlation between each baseline parameters. Sec-
ondary outcomes assessed at baseline significantly correlated with ΔBM has been considered
potential predictors of involuntary weight loss for W and M with AD. The interaction between
Weight Loss in Alzheimer's Disease
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potential predictors of ΔBM in W and M with AD was then calculated with a forward stepwise
regression model.
Statistical analysis
Raw data were analyzed using a statistical software package (StatPlus, AnalystSoft Inc.—statis-
tical analysis program for Mac OS1. Version v6. See http://www.analystsoft.com/en/). To
check the normal distribution of the sampling, a Shapiro-Wilk test was applied. Whether this
test failed, a non-parametric approach was applied. In consideration of preliminary results on
salivary cortisol, hematological and blood chemistry measurements, and energy expenditure
calculation, a sample size of 80 participants was selected to ensure a statistical power higher
than 0.80 and a type 1 error of<0.05. Intention to treat approach was utilized to analyze the
experimental data: missing values (participants dropout) were considered in the statistical anal-
ysis. A two-way (group x time) analysis of variance (ANOVA) was used to establish statistical
differences among conditions. When necessary, a Bonferroni post-hoc, with Bonferroni correc-
tion test, was used to determine specific differences and interactions among variables A Krus-
kal Wallis ANOVA on ranks was applied to establish statistical differences among conditions
presenting a non-normal distribution. Significance level was set at α<0.05. Results are pre-
sented as mean ± standard deviation (SD).
Results
Characteristics of the participants
363 individuals were screened for eligibility; 171 qualified (85 residents of the Alzheimer’s care
units with a confirmed diagnosis of Alzheimer’s diseases and 86 without clinical evidence of
dementia) were followed during the standard institutionalized diet. Table 1 displays the base-
line characteristics of the study population. At baseline groups were matched for age, sex, body
mass index (BMI), and coexisting chronic conditions. According to the CDR scale patients
with AD were at the 2nd stage of the dementia development, with an average time from Alzhei-
mer’s disease diagnosis of 8 ± 2 years. Antidementia drugs and other medications taken by the
two groups are displayed in Table 1.
Adherence to the standard institutionalized diet and health-related
dropout
No adverse events related to the standard institutionalized diet were observed. Distribution of
diet-adherence in patients with AD and CTRL is represented in Fig 2. Mean adherence was
96 ± 3% in the group of AD, and 95 ± 3% in the CTRL group, respectively (p = 0.9). During the
observation period, no changes in the category of medications taken by the AD and CTRL
were recorded. The follow-up time of the present cohort study was 372 ± 12 days, from January
2014 to January 2015. Five patients with AD (6% of the AD group) left the study to serious
medical condition (2 strokes and 3 dysphagias). Three participants of the control group (4% of
the CTRL group) also left the program because of serious health problems (1 heart attack and 2
strokes). In line with the intention to treat statistical approach, PRE values of dropouts were
included for comparisons.
Primary outcome
Mean (± SD) inter- and intra-group differences in primary outcomes at baseline and 12
months are shown in Fig 3. After intervention, patients with AD demonstrated a significantly
reduction in BM (-2.5 kg; p< 0.01), while in CTRL remained unchanged (-0.4 kg; p = 0.8).
Weight Loss in Alzheimer's Disease
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Secondary outcomes
After the standard institutionalized diet none of the selected secondary outcomes and hemato-
logical and blood chemistry measurements were significantly changed in the group of AD
patients and CTRL (Table 2). However, AD patients demonstrated at baseline and after the
period of the standard institutionalized diet, a chronic inflammatory state revealed by the ele-
vated levels of WBC (p< 0.01), primarily due to the increased fraction of Neutrophil (Table 3).
ALB plasma levels in AD were lower than in CTRL both at baseline (p< 0.01) and after the
observation period (p< 0.01). Retinol blood level was similar between the two groups
Fig 2. Distribution of diet-adherence in patients with AD and CTRL.
doi:10.1371/journal.pone.0157384.g002
Fig 3. bodymass at baseline (PRE) and after 12 months (POST) of controlled diet. *P<0.05 vs PRE;
†P<0.05 vs CTRL.
doi:10.1371/journal.pone.0157384.g003
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Table 2. Hematological and blood chemistry measurements at baseline (PRE) and after 12 months (POST) of controlled diet.
Measure CTRL AD
PRE (n. 86) POST (n. 83) PRE (n. 85) POST (n. 80)
Glucose (mg!dl-1) 88 ± 4 88 ± 4 87 ± 3 87 ± 3
RBC (106!μl-1) 3.90 ± 0.26 3.96 ± 0.19 3.96 ± 0.21 3.95 ± 0.20
Hb (g!dl-1) 12.9 ± 0.88 13.3 ± 0.92 12.8± 0.84 13.1± 0.85
HDL (mg!dl-1) 51.8 ± 1.4 52.3 ± 1.4 51.9 ± 1.2 51.8 ± 1.0
LDL (mg!dl-1) 98.3 ± 2.7 97.9 ± 2.7 98.5 ± 3.0 97.9 ± 3.1
Creatinine (mg!dl-1) 0.67 ± 0.09 0.66 ± 0.09 0.66 ± 0.09 0.65 ± 0.07
Azotemia (mg!dl-1) 34.6 ± 5.44 34.3 ± 4.95 34.8 ± 5.53 36.9 ± 5.66
Na+ (mEq!l-1) 142.6 ± 3.10 142.3 ± 3.30 142.3 ± 3.75 142.0 ± 3.11
K+ (mEq!l-1) 3.80 ± 0.43 3.73 ± 0.44 3.74 ± 0.46 3.73 ± 0.42
Cl- (mEq!l-1) 101.8 ± 3.13 102.2 ± 3.03 102.1 ± 3.44 102.1 ± 3.06
AST (U!l-1) 32.8 ± 12.7 29.8 ± 13.9 30.3 ± 12.9 30.5 ± 13.2
ALT (U!l-1) 25.7 ± 9.8 25.2 ± 10.1 26.1 ± 10.8 23.6 ± 10.3
GTP (U!l-1) 19.9 ± 7.0 19.9 ± 7.6 19.9 ± 7.6 19.1 ± 6.9
Bilirubin (mg!dl-1) 0.67 ± 0.23 0.61 ± 0.24 0.61 ± 0.20 0.65 ± 0.22
Bilirubin dir (mg!dl-1) 0.20 ± 0.07 0.21 ± 0.08 0.18 ± 0.07 0.20 ± 0.08
Bilirubin fra (mg!dl-1) 0.47 ± 0.23 0.39 ± 0.27 0.43 ± 0.21 0.44 ± 0.21
doi:10.1371/journal.pone.0157384.t002
Table 3. Inflammation, antioxidant carrier, nutritional state, cardiovascular, cognitive, functional state, number of medications, energy intake,
daily energy expenditure, restingmetabolic rate (RMR), and energy consumed by physical activity (PA) at baseline (PRE) and after 12 months
(POST) of controlled diet.
Measure CTRL AD
PRE (n. 86) POST (n. 83) PRE (n. 85) POST (n. 80)
WBC (n!μl-1) 6102 ± 1151 5909 ± 1109 8670 ± 1129 † 8597 ± 1044 †
Neutrophil (% of total) 55.3 ± 5.8 54.3 ± 6.0 67.7 ± 4.5 † 66.3 ± 7.9 †
Eosinophil (% of total) 3.00 ± 1.63 3.20 ± 1.80 3.65 ± 1.65 3.51 ± 1.47
Basophil (% of total) 0.96 ± 0.83 0.97 ± 0.82 0.97± 0.84 0.94± 0.78
Lymphocytes (% of total) 28.3 ± 4.3 27.1 ± 5.0 26.9 ± 4.5 27.1± 4.5
Mon. mac. (% of total) 5.9 ± 2.6 5.9 ± 2.4 5.8 ± 2.3 6.5± 2.4
Albumin (g!dl-1) 4.38 ± 0.30 4.38 ± 0.26 3.00 ± 0.53 † 2.97 ± 0.57 †
Retinol (μg!dl-1) 45.8 ± 1.9 45.5 ± 2.0 45.1 ± 2.3 45.5 ± 1.8
Systolic BP (mmHg) 127 ± 9 126 ± 7 132 ± 9 † 131 ± 9 †
Diastolic BP (mmHg) 82 ± 3 82 ± 2 81 ± 4 80 ± 4
MMSE (0–30) 28 ± 2 28 ± 2 13 ± 2 † 12 ± 2 †
Barthel (0–100) 49 ± 8 50 ± 9 52 ± 9 51 ± 9
Balance test (0–16) 12 ± 2 12 ± 2 13 ± 2 13 ± 2
Gait test (0–12) 10 ± 1 10 ± 1 10 ± 1 10 ± 1
NMED 3 ± 1 3 ± 1 6 ± 1 † 6 ± 1 †
Energy intake (kcal!24h-1) 1804 ± 157 1810 ± 163 1804 ± 159 1812 ± 140
Energy expenditure (kcal!24h-1) 1629 ± 153 1614 ± 152 1640 ± 132 1610 ± 128
RMR (kcal!24h-1) 1059 ± 99 1049 ± 102 1066 ± 86 1046 ± 83
PA (kcal!24h-1) 570 ± 54 564 ± 53 574 ± 46 563 ± 45
† P<0.05 vs CTRL.
doi:10.1371/journal.pone.0157384.t003
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(Table 3). COR levels were significantly higher in the AD group at each time point (6.30, 11.30
and 18.30) compared to CTRL at both baseline and after the observation period (Fig 4). Systolic
blood pressure was 5.2 mmHg higher in the AD patients at baseline; this difference was main-
tained (+4.4 mmHg) after the observation period. As expected, cognitive level of patients with
AD was significantly lower compared to CTRL (Table 3). AD patients did not exhibit further
decreases in MMSE during the 12-month of standard institutionalized diet. NMED taken by the
patients with AD was significantly higher compared to CTRL (Table 3). Specifically, AD
patients were treated with Quetiapine (32±7%), Citalopram (26±4%), Donepezil (6±2%),
Memantine (2±1%), Ticlopidin (12±4%), Furosemide (15±3%). Additionally, the energy intake
calories calculated from the daily eaten meals, and the adherence to the diet program (Fig 2),
indicated a similar daily energy ingestion in AD patients and CTRL (Table 3). Interestingly,
DEE, divided in PA and RMR, was similar in both groups (Table 3).
Predictors of BM changes in patients with AD
Secondary outcomes assessed at baseline in patients with AD are represented with age- and
sex-adjustment in Table 4. The 55 W with AD were significantly different in comparison to the
25 M with AD in terms of BM, number of red blood cells, systolic blood pressure, behavioral
disturbance, salivary levels of cortisol, and daily energy intake. No difference in secondary out-
comes, expect for the the duration of disease, has been detected between patients with AD
adjusted for age (Table 4).
The univariate Pearson’s correlation model applied to the secondary outcomes assessed at
baseline in the groups of W and M with AD are displayed in Tables 5 and 6 respectively. In the
group of W with AD the baseline secondary outcomes significantly correlated with ΔBM were
the NMED, ALB, NPI, COR, and BM (Table 5). Conversely, in the group of M with AD the base-
line values significantly correlated with ΔBM were the NMED, ALB, NPI, MMSE, and COR
Fig 4. Circadian secretion of salivary cortisol. AD, Patients with Alzheimer’s disease; CTRL, aged
matched controls; Avg, daily averaged cortisol. †P<0.05 vs CTRL.
doi:10.1371/journal.pone.0157384.g004
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(Table 6). The forward stepwise regression models utilized for the calculation of the interaction
between the significantly correlated secondary outcomes assed at baseline and the ΔBM in W
and M with AD are displayed in Tables 7 and 8. The forward stepwise regression utilized for
the prediction of ΔBM in W with AD revealed that the combination of 3 factors NMED, ALB,
and COR can predict this clinical phenomenon (Table 7). While at contrary, the best predictor
of ΔBM in M with AD was the COR (Table 8).
Discussion
The main finding of the present cohort study was that involuntary WL, determined by BM
reduction in patients with AD was not influenced by patients’ energy intake. Additionally, our
data of DEE suggest that the changes in BM of patients with AD were not affected by their
metabolism rate. Conversely, the combination of others factors, i.e., hypoalbuminemia, num-
ber of medications, and hypercortisolism, contributed to the involuntary WL in the present
Table 4. Baseline characteristics of patients with AD adjusted by sex (women (W); men (M)) and age (less than 75 yrs; between 75 and 80 yrs;
more than 80 yrs).
Measure ADsex ADage
W (n. 55) M (n. 25) <75 yrs (n. 29) 75–80 yrs (n. 32) >80 (n. 16)
Age (yrs) 77 ± 5 76 ± 4 72 ± 2 77 ± 2 83 ± 2
Body mass (kg) 57.8 ± 5.5 69.9 ± 4.1 * 61.0 ± 8.1 62.8 ± 6.9 60.2 ± 7.7
Duration of disease (yrs) 8 ± 2 7 ± 2 6 ± 2 7 ± 2 10 ± 1 §
NMED (n) 6 ± 1 6 ± 1 4 ± 1 4 ± 1 4 ± 1
Ncomorbit (n) 2 ± 1 2 ± 1 2 ± 1 2 ± 1 2 ± 1
WBC (n!μl-1) 8684 ± 1122 8733 ± 1145 8761 ± 1158 8815 ± 1173 8367 ± 942
ALB (g!dl-1) 3.01 ± 0.55 3.03 ± 0.39 2.97 ± 0.47 3.04 ± 0.42 3.03 ± 0.68
Retinol (μg!dl-1) 45.4 ± 2.3 44.9 ± 2.4 45.3 ± 2.2 44.8 ± 2.6 45.8 ± 1.8
Glucose (mg!dl-1) 87 ± 3 87 ± 3 87 ± 3 87 ± 3 88 ± 4
RBC (106!μl-1) 3.92 ± 0.24 4.02 ± 0.13 * 3.99 ± 0.17 3.96 ± 0.25 3.86 ± 0.20
Hb (g!dl-1) 12.9 ± 0.9 12.9 ± 0.9 12.7 ± 0.8 12.9 ± 0.8 13.0 ± 0.9
HDL (mg!dl-1) 51.9 ± 1.2 52.1 ± 1.2 52.2 ± 1.3 51.7 ± 0.9 52.1 ± 1.3
LDL (mg!dl-1) 98.0 ± 3.1 98.8 ± 2.9 97.8 ± 1.4 98.1 ± 3.5 99.2 ± 4.0
SBP (mmHg) 134 ± 10 128 ± 8 * 132 ± 11 132 ± 8 134 ± 10
DBP (mmHg) 81 ± 5 80 ± 3 81 ± 4 80 ± 5 81 ± 4
MMSE (0–30) 13.1 ± 1.7 13.6 ± 1.6 13.3 ± 1.6 13.3 ± 1.8 13.1 ± 1.7
Barthel (0–100) 53 ± 9 50 ± 10 53 ± 10 50 ± 9 53 ± 8
Behavioral disturbance (NPI) 63 ± 19 76 ± 17 * 69 ± 19 68 ± 22 63 ± 15
COR (nmol!l-1) 9.5 ± 2.0 10.5 ± 1.6 * 9.9 ± 2.0 9.7 ± 2.1 9.7 ± 1.2
Balance test (0–16) 13 ± 2 12 ± 1 13 ± 2 13 ± 2 13 ± 2
Gait test (0–12) 10 ± 1 10 ± 1 10 ± 1 10 ± 1 10 ± 1
Energy intake (kcal!24h-1) 1775 ± 161 1859 ± 137 * 1799 ± 163 1765 ± 147 1875 ± 152
Energy expenditure (kcal!24h-1) 1637 ± 144 1640 ± 120 1644 ± 117 1629 ± 144 1656 ± 153
RMR (kcal!24h-1) 1065 ± 93 1066 ± 78 1078 ± 77 1058 ± 93 1038 ± 99
PA (kcal!24h-1) 573 ± 50 574 ± 42 579 ± 41 570 ± 50 581 ± 53
Number of medications taken (NMED); number of comorbidities (Ncomorbit); white blood cells (WBC); plasma level of albumin (ALB); red blood cells (RBC);
hemoglobin (Hb); high density lipoprotein (LDL); low density lipoprotein (LDL); systolic blood pressure (SBP); diastolic blood pressure (DBP); salivary level of
cortisol (COR); cognitive function (MMSE); severity of behavioral disorders (NPI); resting metabolic rate (RMR); energy consumed by physical activity (PA).
* P<0.05 vsW
§ P<0.05 vs <75yrs.
doi:10.1371/journal.pone.0157384.t004
Weight Loss in Alzheimer's Disease
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group of W with AD. Conversely, data of M with AD followed in this cohort study indicate
that WL was primarily correlated with the baseline values of salivary cortisol. Indeed, involun-
tary WL in patients with AD is a multifaceted clinical phenomenon, and in the current cohort
study we were able to establish, at list in part, some of the factors associated with involuntary
WL. The overall plausible causal mechanisms linking AD andWL, including the potential
pathways and the biomarkers utilized in this study, are displayed in the schematic Fig 5.
Energy intake and involuntary WL
AD is typically associated with nutritional disorders [6]. It has been demonstrated that the WL
usually exhibited by old individuals with dementia can be attenuated by increasing their energy
intake [3]. However, Singh et al. [21] reported that WL in patients with AD was not accompa-
nied by any apparent deficit in food intake or malabsorption. Accordingly, data from the cur-
rent cohort study indicate that even in a condition of controlled standard institutionalized diet,
the present groups of W and M with AD suffered of a remarkable WL. Noticeably, at baseline
and after the 12-month of standard institutionalized diet, the blood level of retinol was similar
in the two groups, implicating the adequacy of the energy intake adopted in this cohort study.
Thus, unilateral approaches based upon controlled standard institutionalized diets seem not to
be adequate to prevent and control this clinical phenomenon (Fig 5).
Metabolic rate and involuntary WL
In previous investigations, the potential association between metabolism, AD andWL has been
investigated, since a disproportion between energy intake and energy expenditure could pro-
duce WL [6]. In AD individuals a high energy expenditure could be induced by an elevated
RMR, and by the increased levels of PA due to behavioral disorders, such as wandering. Inter-
estingly, Knight et al. [4] examined the longitudinal variations of BM, food intake, and meta-
bolic rate in a triple-transgenic mouse model of AD, and revealed a raised RMR. However,
when moving into investigations involving humans, such results are controversial [5, 22]. Data
from the current study indicate a RMR similar between individuals with AD and controls, and
Table 8. Forward stepwise regression of secondary outcomes assed at baseline which predictΔBM
in M with AD. salivary level of cortisol (COR).
Stepwise regression (M)
R R-square Adjusted R-square S F p-level
0.78248 0.61227 0.59541 1.53055 36.31949 0.0000
VAR Coefﬁcient Standard Error Beta t p-level > t VIF TOL
COR -1.20991 0.20076 -0.78248 -6.02657 0.000000 1. 1.
Intercept 10.76826
doi:10.1371/journal.pone.0157384.t008
Table 7. Forward stepwise regression of secondary outcomes assed at baseline which predictΔBM
inWwith AD. number of medications taken (NMED); plasma level of albumin (ALB); salivary level of cortisol
(COR).
R R-square Adjusted R-square S F p-level
0.7991 0.63855 0.61687 1.46772 29.44453 0.0000
VAR Coefﬁcient Standard Error Beta t p-level > t VIF TOL
NMED -1.10148 0.19398 -0.52329 -5.67832 0.00000 1.17484 0.85118
ALB 1.38111 0.40977 0.31952 3.37049 0.00145 1.24319 0.80438
COR -0.30862 0.10327 -0.26234 -2.98855 0.00434 1.06596 0.93812
Intercept 0.20344
doi:10.1371/journal.pone.0157384.t007
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no correlation between RMR and involuntary WL in both W and M with AD. Thus, in agree-
ment with the literature on humans [5, 23], it seems that the BM changes cannot be ascribed to
an elevated RMR. Moreover, wandering, a typical clinical sign of aberrant motor behavior in
patients with AD has been hypothesized to increase levels of PA, thus possibly affect BM
changes [6]. Conversely, Secher et al. [24] revealed that AD patients with elevated behavioral
disturbances even gained body weight. In addition, Poehlman et al., [23] observed reduced lev-
els of PA in patients with AD compared to healthy elderly controls. The results of the present
cohort study indicate that the energy expenditure related to PA was not different between indi-
viduals with AD that suffered of behavioral disturbances, and age-matched controls without
dementia (Table 3). Moreover, the poor correlation between PA and ΔBM in W and M with
AD (Tables 5 and 6) suggest that the etiology of WL observed in patients with AD is likely
influenced by other factors (Fig 5).
Hypoalbuminemia and involuntary WL
The well-recognized body composition changes in patients with AD are similar, yet more
severe, to the standard age-related sarcopenia. All the most credited theories of aging agree that
age-related accumulation of reactive oxygen species is a main contributor of cellular senes-
cence, and this factor clearly contribute to the skeletal muscle atrophy [25, 26]. In this context,
Fig 5. Causal mechanisms linking Alzheimer’s disease (AD) and involuntary weight loss (WL). Resting metabolic rate (RMR);
daily physical activity (PA); hypothalamic–pituitary–adrenal axis (HPA-axis); reactive oxygen species (ROS).
doi:10.1371/journal.pone.0157384.g005
Weight Loss in Alzheimer's Disease
PLOS ONE | DOI:10.1371/journal.pone.0157384 June 27, 2016 14 / 18
the literature highlights a close correlation between the levels of reactive oxygen species and
AD [11]. Moreover, Kim et al. [12] indicated that the major plasma carrier of antioxidants,
albumin, was significantly reduced in patients with AD. In agreement, results of the current
cohort study suggest that in W with AD a reduction of plasma levels of albumin, in combina-
tion with the chronic poli-pharmacological treatment adopted (that additionally reduces anti-
oxidant binding capacity of albumin), significantly affected BM (Fig 5). Therefore, particular
attention should be taken in the evaluation of the plasma levels of albumin in W with AD,
because this parameter may predict a possible reduction of BM.
Chronic inflammation state and involuntary WL
It has been reported that peripheral leukocytes are altered in patients with AD [27]. Remark-
ably, the elevation in oxidative stress markers is also associated with an increased number of
neutrophils [13]. Therefore, it may be reasonably expected a role of the chronic inflammation
in the BM changes in patients with AD. However, the results from the current cohort study
suggest that the chronic inflammation state, demonstrated by the elevated levels of neutrophils,
was not correlated to the 12-month changes in BM for both W and M with AD. Therefore, the
relevance of the chronic inflammation in the development of body composition changes in
patients with AD does not seem to be crucial (Fig 5).
Poli-pharmacological treatment and involuntary WL
Patients with AD are chronically treated with several medications, and the potential effect of
these drugs onWL has been already investigated. For instance, in previous studies [7, 24] the
effect of cholinesterase inhibitors onWL in patients with AD has been debated, but with con-
troversy. In addition, pharmacological interactions among medications may potentially exacer-
bate the side effects or may produce malabsorption of macro and micro nutriments thus
influencing body composition. Interestingly, the number of drugs daily taken by both W and
M with AD in this study was correlated to WL. This circumstance, in combination with the
simultaneous diminished albumin plasma levels, likely reduced the bulk delivery of antioxi-
dants (Fig 5). Therefore, attention should be taken for the prescription of additional medica-
tions, with particular focus on the total number of drugs daily taken by patients.
Hypercortisolism and involuntary WL
HPA-axis activity is altered in patients with AD [9, 28]. The effects of such dysregulation are
wide-ranging, but the most evident consequence is an increase in cortisol levels. The hypercorti-
solism in patients with AD is correlated with the exacerbation of behavioral disorders, such as the
sundowining syndrome [9, 29]. Elevated levels of cortisol, one of the most catabolic hormones,
lead also to a remarkable sarcopenia. Interestingly, data from the current cohort study confirm
that in bothW andM with AD the cortisol levels were significantly higher (Fig 4). Noticeably,
these elevated values of cortisol were significantly correlated (r = 0.785 and r = 0.746) with the
severity of behavioral disorders estimated with the NPI test (Tables 5 and 6) for W andM with
AD respectively. Most importantly, the BM changes in 12 months were significantly correlated
with the elevated cortisol levels (Tables 5 and 6; Fig 5). Therefore, the cortisol levels, which are
not routinely assessed in patients with AD, would help to predict patients at risk of WL.
Predictors of involuntary WL in W and M with AD
Our data has revealed that sex was a potential covariant for ΔBM, in W and M with AD. There-
fore, to establish potential single correlation between each baseline parameters and ΔBM in W
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and M with AD univariate Pearson’s correlation models were performed. Secondary outcomes
assessed at baseline that were significantly correlated with ΔBM have been considered as poten-
tial predictors of involuntary WL for W and M with AD (Tables 5 and 6). Moreover, the result
of the forward stepwise regression model suggests that ΔBM inW with AD (Table 7) can be
predicted by the combination of three factors: NMED, ALB, and COR. For instance, a W with
AD that is treated with 4 different medications, have ALB values of 3.03 g!dl-1, and salivary
COR levels of 9.5 nmol!l-1 will probably lose*3 kg of BM during one year of her institutional-
ized life. Conversely, WL in M with AD appears to be mainly related to the COR levels
(Table 8). In this case, a M with AD with a salivary COR levels of 10.6 nmol!l-1 will probably
lose*2 kg of BM during one year of his institutionalized life.
Conclusion
Patients with AD that suffered of involuntary WL are at high risk of frailty and mortality. This
phenomenon is multifactorial and the etiology could be related to the inadequacy of energy
intake. However, the results of the current cohort study highlighted the critical role of the
hypoalbuminemia, the number of medications taken, and the hypercortisolism, in BM changes
in W with AD. Conversely, involuntary WL in M with AD appears mainly associated with
hypercortisolism. It is important to note, that data from the current study, especially taking
into account energy expenditure values, are based upon institutionalized individuals and such
results may not be applied to community living elderly.
Nevertheless, the assessment of these values in a clinical milieu, and their correct utilization
into the equations for W and M with AD extrapolated from the current investigation, may be
helpful in predicting this challenging clinical phenomenon.
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